NAD+ (nicotinamide adenine dinucleotide) is a coenzyme found in every cell that powers energy production, DNA repair, and aging-related gene regulation — and is commonly supplemented via IV or precursor compounds to counter age-related decline.
What it does
NAD+ sits at the center of cellular metabolism. As an electron carrier in the mitochondrial electron transport chain — the process cells use to convert nutrients into usable energy — it is indispensable for oxidative phosphorylation. Without adequate NAD+, mitochondria run inefficiently Pankaj 2025. Every living cell depends on it for more than 500 enzymatic reactions.
Two enzyme families consume NAD+ for critical maintenance work. Sirtuins (SIRT1–7) are deacetylases — proteins that strip acetyl chemical tags off histones and other proteins, regulating gene expression, DNA repair, inflammation, and mitochondrial health Jia 2025 Songyuan 2025 Ruo-Ran 2025. They cannot function without NAD+ as a co-substrate, which means falling NAD+ levels directly slow down this repair and regulation machinery. PARP enzymes (poly ADP-ribose polymerases) use NAD+ to patch DNA strand breaks; chronic DNA damage drains NAD+ pools, which in turn impairs repair — a self-reinforcing cycle Saba 2025.
NAD+ levels fall roughly 50% between ages 40 and 60. A key driver is CD38, an immune-signaling enzyme whose expression rises with age and aggressively consumes NAD+ Saba 2025. The result is simultaneous decline in sirtuin activity, DNA repair capacity, and mitochondrial output — a convergence that the 'NAD+ decline theory of aging' argues underlies much of age-related cellular dysfunction Geicianny 2026 Huiying 2025.
What the evidence shows
Aging and cellular longevity Strong mechanistic and rodent evidence; human trial data emerging but limited
In aged mice, restoring NAD+ levels through precursors like NMN (nicotinamide mononucleotide) improved metabolic health markers and physical performance Yi-Ju 2025. Skin fibroblast studies show NMN supplementation produces gene expression profiles consistent with reduced cellular senescence — the state where cells stop dividing and drive inflammation Seongsu 2025. SIRT6, one of the NAD+-dependent sirtuins, has been linked to lifespan extension in animal models and is an active target for therapeutic research Ruo-Ran 2025 Geicianny 2026. Human randomized trials are underway but the field lacks large, long-duration outcomes data in people.
Muscle preservation and mitochondrial function Rodent and cell-culture evidence; human data limited
NAD+ boosting via NAMPT (nicotinamide phosphoribosyltransferase, the enzyme that synthesizes NAD+ inside cells) has been shown to improve SIRT1-driven mitochondrial function in muscle tissue, reducing atrophy markers in animal models Jia 2025. Aged-mouse aerobic exercise studies combining NMN supplementation with training showed additive improvements in endurance and metabolic markers Yi-Ju 2025. Whether these translate directly to humans at clinical doses remains an open question.
Skin aging Cell-culture and small human data; mechanistic rationale is solid
NAD+ precursor treatment of human keratinocytes (skin surface cells) modulated senescence pathways and reduced markers of cellular aging Jung 2025. Fibroblast gene expression studies found NMN activates longevity-associated pathways in skin cells specifically Seongsu 2025. This supports topical and systemic NAD+ strategies for skin aging, though clinical trial evidence in this area is thin.
Eye and retinal protection Animal and mechanistic evidence; limited human clinical data
NAD+ boosting strategies show protective effects against retinal degeneration in preclinical models, likely through sirtuin activation and mitochondrial stabilization in photoreceptors and retinal pigment epithelium Saba 2025. Human trials have not yet established clinical dosing or efficacy for retinal disease.
Addiction and withdrawal support Anecdotal and clinic-reported; no robust controlled trial data
High-dose IV NAD+ (1,000 mg daily for 10 days) is used in some addiction medicine clinics to ease withdrawal symptoms and reduce cravings, based on the hypothesis that addiction depletes NAD+ and impairs neurological recovery. The mechanism is plausible given NAD+'s role in neuronal energy metabolism, but controlled human trial evidence is absent. This protocol is based almost entirely on clinical observation.
How it's used
In studies and self-reported protocols, doses vary widely by route. Subcutaneous injections run around 100 mg daily. IV infusions range from 250 mg weekly at the low end to 500 mg two to three times weekly for general wellness protocols, up to 1,000 mg daily for 10 days in addiction-focused settings. IV infusions are administered slowly over 2–4 hours to minimize flushing, chest tightness, and nausea — running the drip faster reliably worsens side effects. Intranasal and intramuscular routes exist but are less common. Because NAD+ itself has a systemic half-life of roughly 10 minutes, oral NAD+ is largely ineffective; oral supplementation instead uses precursors — NMN or NR (nicotinamide riboside) — which cells convert into NAD+ intracellularly. Oral precursor dosing in human studies has ranged from 250 mg to 1,000 mg daily.
Side effects and safety
The most consistent side effects with IV administration are flushing, nausea, chest tightness, and abdominal cramping — all tied to infusion rate and largely avoidable by slowing the drip. Headache, post-infusion fatigue, insomnia, and anxiety are reported at moderate frequency, particularly at higher doses. Severe bradycardia (dangerously slow heart rate) has been reported with rapid IV administration. Liver toxicity has been flagged at very high doses, though documented cases are rare. People with significant anxiety disorders should approach IV protocols cautiously, as the infusion can acutely worsen anxiety symptoms. NAD+ is considered relatively contraindicated during active severe infection given theoretical inflammatory amplification, and data in pregnancy are essentially absent. Long-term safety data — particularly for repeated high-dose IV use — does not exist in any rigorous form. Oral precursors (NMN, NR) have a cleaner short-term safety profile from available human trials, but multi-year data is lacking for those as well.
Bottom line
NAD+ has one of the most compelling mechanistic cases in the longevity space — the biology connecting NAD+ decline to aging is well-established and the rodent evidence is strong. Human trial data, however, is still catching up: most protocols in clinical use are ahead of the controlled evidence. It's a reasonable consideration for people focused on cellular aging and metabolic health who understand they're working with promising but incomplete data.